Filed in archive
Drugs, Vaccines and Therapeutics
by ruth on January 16, 2009
The FDA has approved a new drug for the management of fibromyalgia. Savella™ (milnacipran HCl), developed by FOREST LABORATORIES, Inc.and Cypress Bioscience, Inc., is a selective serotonin and norepinephrine dual reuptake inhibitor.
Two US phase III clinical trials involving over 2,000 patients with fibromyalgia have shown that Savella doses of 100 mg/day and 200 mg/day resulted to statistically significant and clinically meaningful concurrent improvements in pain,
patient global assessment, and physical function.
The companies expect Savella to be available in pharmacies by March 2009. Savella will be third FDA-approved fibromyalgia drugs, which include the nerve pain drug Lyrica and the SNRI antidepressant Cymbalta.
Source (pdf)
Two US phase III clinical trials involving over 2,000 patients with fibromyalgia have shown that Savella doses of 100 mg/day and 200 mg/day resulted to statistically significant and clinically meaningful concurrent improvements in pain,
patient global assessment, and physical function.
The companies expect Savella to be available in pharmacies by March 2009. Savella will be third FDA-approved fibromyalgia drugs, which include the nerve pain drug Lyrica and the SNRI antidepressant Cymbalta.
Source (pdf)
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/141388
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for FDA Approves Savella for treatment of Fibromyalgia:
|
Rating: 7.40 out of 5 vote(s) cast.
|
Response from:
Melissa
(08/11/09 11:11am)
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
Melissa Davis